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Vaccine development for the blood stages of malaria has focused on the induction of antibodies to parasite 
surface antigens, most of which are highly polymorphic. An alternate strategy has evolved from observa-
tions that low-density infections can induce antibody-independent immunity to different strains. To test 
this strategy, we treated parasitized red blood cells from the rodent parasite Plasmodium chabaudi with seco-
cyclopropyl pyrrolo indole analogs. These drugs irreversibly alkylate parasite DNA, blocking their ability 
to replicate. After administration in mice, DNA from the vaccine could be detected in the blood for over 110 
days and a single vaccination induced profound immunity to different malaria parasite species. Immunity 
was mediated by CD4+ T cells and was dependent on the red blood cell membrane remaining intact. The 
human parasite, Plasmodium falciparum, could also be attenuated by treatment with seco-cyclopropyl pyr-
rolo indole analogs. These data demonstrate that vaccination with chemically attenuated parasites induces 
protective immunity and provide a compelling rationale for testing a blood-stage parasite-based vaccine 
targeting human Plasmodium species.
Introduction
The development of a vaccine for malaria is seen as the best hope 
to significantly reduce the burden of disease (1–3). Vaccine devel-
opment for the blood stages has focused on individual antigens 
expressed on the parasite or infected rbc surface primarily because 
antibodies induced by recombinant forms of these antigens can 
induce immunity in model systems. However, despite initial 
promise with one vaccine candidate, MSP2 (4), none of these sub-
unit vaccine approaches have translated to success in late-stage 
clinical trials (e.g., refs. 5, 6), although there has been no follow-
up with MSP2. Evidence suggests that this is in large part due to 
the extensive polymorphisms that occur in these proteins (7) and 
to the fact that very high titer antibody responses are required for 
efficacy (8, 9). Virtually all vaccine trials have focused on Plasmo-
dium falciparum, even though the other species that infect humans, 
particularly Plasmodium vivax, also cause significant morbidity 
and mortality (10).
Over the last 10 years, evidence has accumulated that low-
density blood-stage infections that are curtailed by antimalaria 
drug therapy (and in which parasitemia is below the threshold 
detectable by microscopy) can induce immunity in both human 
and rodent systems (11, 12). Although further work is required 
to validate results from human volunteers (11), due to concerns 
with the half-life of the drug previously used (13), in rodent 
models, immunity was shown to be species- and strain-transcen-
dent (12). Unlike immunization with a subunit vaccine, expo-
sure to whole organisms has the advantage of inducing immune 
responses to multiple plasmodial antigens, many of which are 
likely to be highly conserved between strains or species (14). An 
additional difference between subunit vaccination and immuni-
ty induced by exposure to a low-density infection is that immu-
nity in the latter is antibody independent and T cell dependent 
(11, 12). While high parasite load is a critical determinant driv-
ing T cells to undergo apoptosis during normal infection, expo-
sure to parasites at low density leads to T cell activation (11, 15). 
In humans, this immunity involves both CD4+ and CD8+ T cells 
as well as induction of nitric oxide synthase and the absence of 
any detectable antibody response to defined merozoite surface 
proteins or to antigens expressed on the surface of infected rbcs 
(11). Subsequent experiments demonstrated that low doses of 
Plasmodium chabaudi parasites killed by freeze/thawing, when 
combined with the Th1 T cell–activating adjuvant CpG, could 
also induce antibody-independent immunity to various strains 
and species of Plasmodium (16). The adjuvant was critical for vac-
cine efficacy. Others have recently shown protection following 
immunization with low doses of nucleoside transporter-1 geneti-
cally attenuated Plasmodium yoelii blood-stage parasites which 
induced a limited microscopic infection during the immuniza-
tion period (17). However, these approaches are marred by dif-
ficulties in identifying a suitable human-compatible adjuvant 
capable of replicating the immunity induced in mice by killed 
parasites (16) and concerns that a parasite genetically modified 
in only one or a few regions of its genome might revert to a viru-
lent phenotype (18).
Given that exposure to live parasites at low density (without 
an adjuvant) induces immunity, we asked whether low doses of 
live blood-stage parasites attenuated by a chemical treatment 
that irreversibly alkylates the parasite’s DNA in multiple sites 
(19) could also induce immunity. While chemically attenuated 
intact sporozoite stage parasites (the stage inoculated by mosqui-
toes and which travel to the liver to continue their life cycle) can 
induce immunity (20, 21), DNA chemical attenuation of blood 
stages has never been pursued as a vaccine strategy.
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Results
Attenuated parasites persist and induce cross-species protective immunity. 
We initially treated P. chabaudi parasitized rbcs (prbcs), 98% of 
which were at the early “ring” stage, with the seco-cyclopropyl pyr-
rolo indole analogs AS-I-145 (centanamycin), TH-III-149 (tafura-
mycin A), and AS-VIII-104 for 40 minutes in vitro. The prbcs were 
washed 3 times to remove excess drug, and then 106 treated cells 
were administered i.v. to immunodeficient SCID mice to ascer-
tain attenuation. Mice were followed for 6 weeks for the appear-
ance of any “breakthrough,” parasites but none were detected 
microscopically. We also analyzed the blood from SCID and nor-
mal mice receiving centanamycin-attenuated and WT parasites 
using a quantitative PCR (qPCR) assay based on the 18S rRNA 
gene of Plasmodium (Figure 1A). Based on this assay, we showed 
that most attenuated (and WT) parasites were removed from the 
blood within 5 minutes of administration. For up to 24 hours after 
administration of either attenuated or WT parasites to normal 
mice, DNA levels were similar. After that time, DNA levels then 
increased rapidly in mice given WT parasites as the infection pro-
gressed. However, DNA from the attenuated parasites persisted at 
low but fluctuating levels in the blood of SCID and normal mice 
for over 110 days. In a repeat experiment, we used 15 mice and 
divided them into 3 groups of 5 so that more blood could be taken 
from each mouse at each time point up to day 51 (collecting 50 μl 
instead of 20 μl of blood to increase the sensitivity of the assay) 
(Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI66634DS1). As reported in Fig-
ure 1, DNA was detectable at low but fluctuating levels and all 
mice survived. It was not clear whether these low but fluctuating 
levels of DNA represented viable parasites or simply DNA from 
nonviable parasites. To explore further whether or not viable para-
sites were present in the blood of vaccinated mice, xenodiagnosis 
was undertaken. Blood from vaccinated mice was transferred to 
naive BALB/c mice (100 μl per mouse). None of the 20 mice that 
received the blood developed a patent parasitemia, suggesting that 
the parasites were not viable in the donors at the time of transfer.
Parasites attenuated with each of the seco-cyclopropyl pyrrolo 
indole analogs were next administered i.v. to immunocompetent 
A/J mice. The infection is lethal in this mouse strain. Five weeks 
after a single immunizing dose of 106 attenuated P. chabaudi para-
sites, the mice were challenged with 105 homologous WT para-
sites and were strongly protected (Figure 1B). Clinical scores were 
recorded for all mice and none of the vaccinated mice demonstrat-
ed any adverse clinical effects as a result of the vaccination or the 
challenge infection. Although P. chabaudi is not lethal in C57BL/6 
mice, we observed that the centanamycin-attenuated vaccine could 
also induce strong antiparasitic immunity in this mouse strain 
(Figure 1C). In various experiments, control A/J mice immunized 
with uninfected rbcs treated with centanamycin, injected with 
saline, or receiving no treatment all developed a rapid infection 
following challenge and succumbed (data not shown). In other 
experiments, we observed protection following immunization 
with 104 attenuated parasites (data not shown) and also observed 
that 3 immunizations did not lead to enhanced protection over a 
single immunization (Supplemental Figure 2).
We next asked whether immunity was long lived and observed 
that A/J mice challenged 6 months after a single immunization with 
attenuated prbcs from a different parasite, P. yoelii, were strongly 
protected against homologous challenge (Supplemental Figure 3). 
To ask whether immunity resulted in cross-species protection, we 
vaccinated mice with centanamycin-attenuated parasites prepared 
from P. chabaudi strain AS, challenged them with the heterologous 
species, Plasmodium vinckei and P. yoelii, and also observed strong pro-
tection (Figure 1D). Mice were also vaccinated with centanamycin-
attenuated parasites prepared from P. chabaudi strain AS and chal-
lenged initially with the homologous strain, then 3 months later 
with the heterologous strain, P. chabaudi AJ. We observed strong 
protection against the original homologous parasite and the subse-
quent heterologous challenge (Supplemental Figure 4).
Attenuated parasites induce a cellular immune response. To examine 
the nature of immunity, we initially determined the fate of attenu-
ated P. chabaudi prbcs in vivo. We confirmed the rapid diminution 
of attenuated parasite numbers in the blood shown by qPCR (Fig-
ure 1) using an assay in which we tracked parasitized and normal 
rbcs by labeling the rbc membranes with DiI (22) and parasite 
DNA with Hoechst (HO) stain 34580. We demonstrated that 
chemically attenuated prbcs were removed from the circulation 
far more rapidly than normal rbcs (nrbcs) (Figure 2A). Attenuated 
parasites accumulated in the spleen and liver as determined by 
flow cytometry (Figure 2B) and were shown to be inside F4/80+ 
cells (macrophages) and CD11c+ dendritic cells (Figure 2, C and 
D). Confocal imaging confirmed that HO+DiI+ cells could be seen 
within F4/80+ cells in the spleen (Supplemental Figure 5B). These 
data suggested that attenuated parasites might rapidly activate the 
immune system.
To measure early activation of the immune system, we moni-
tored CD11a and CD49d expression on T cells (23) and observed 
that within 5 days of administration of centanamycin-attenu-
ated P. chabaudi prbcs, 1.2% of peripheral blood CD4+ T cells 
showed significant activation above the level of activation in 
mice that received a saline injection (P < 0.0001) and that the 
mean number of activated cells rose to 5% by 21 days (Figure 
3A and Supplemental Figure 6). There was less activation of 
CD8+ cells. When tested 2 months after vaccination, spleen cells 
showed a strong proliferative response to homologous prbcs as 
well as to prbcs of the heterologous species P. yoelii, but not to 
uninfected rbcs (Figure 3B). Spleen cells from a naive mouse did 
not respond to the parasites.
To determine whether the T cells were functional, splenic CD4+ 
and CD8+ T cells were examined for intracellular IFN-γ 5 days 
after vaccination with centanamycin-attenuated parasites, cen-
tanamycin-treated nrbcs, or saline. Cells were activated in vitro 
for 4 hours with PMA/ionomycin prior to staining (as described 
in ref. 23). There were significantly more cytokine-positive cells in 
the spleens of vaccinated mice compared with the other groups of 
mice (Figure 3C). Furthermore, spleen cells from vaccinated mice 
produced larger amounts of IFN-γ and MCP-1 ex vivo in response 
to prbcs compared with nrbcs or medium alone (Figure 3D).
To confirm that vaccination induced expansion and activation 
of antigen-specific CD4+ T cells, rather than bystander activation, 
we transferred congenic (CD45.1) OVA-TCR transgenic OTII cells 
into CD45.2 recipients, which we vaccinated with attenuated para-
sites or OVA peptide/LPS, and observed activation of the OTII cells 
following OVA peptide administration, but not following vaccina-
tion with attenuated parasites. Conversely, we observed activation 
of CD45.2 CD4+ T cells following vaccination with centanamycin-
treated prbcs, but not following administration of centanamycin-
treated nrbcs or OVA. These data demonstrate that the vaccine 
induced expansion and activation of antigen-specific CD4+ T cells, 
without activation of bystander T cells (Figure 3E).
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To determine whether the vaccine-induced, antigen-specific 
CD4+ T cells were protective, immunized mice were given anti-
bodies to clear more than 98% of their CD4+ T cells or more than 
89% of CD8+ T cells (Supplemental Figure 7) and then chal-
lenged. Control mice that received normal rat immunoglobulin 
showed complete protection, but CD4+ T cell–depleted mice all 
succumbed, albeit more slowly than naive mice (Supplemental 
Figure 8). When CD8+ T cells were depleted from immune mice, 
we observed no change in their level of immunity. Thus, CD8+ 
T cells alone are not able to provide complete protection, but 
they or other cell types may contribute a minor role.
Although CD4+ T cells were critical for protection, we were not 
able to transfer protection with purified CD4+ T cells. Thus, 107 
CD45.2 splenic CD4+ T cells from C57BL/6 mice immunized 3 
times with centanamycin-attenuated P. chabaudi prbcs or equiva-
lent numbers of naive CD45.2 T cells were transferred into CD45.1 
congenic naive mice that had been pretreated 3 days earlier with 1 
dose of anti-CD4 mAb to deplete most endogenous T cells. CD4+ 
Figure 1
Immunization with attenuated parasites. (A) Immunodeficient SCID mice (left panel) or immunocompetent A/J mice (right panel) were admin-
istered 106 (left panel) or 107 (right panel) P. chabaudi prbcs attenuated with 2 μM centanamycin or 107 WT parasites (right panel). qPCR was 
performed to estimate parasite density in the blood at various time points. y axes show the estimated parasite density. (B) To assess immunity, 
A/J mice (5 per group) were immunized with a single dose of 106 P. chabaudi prbcs attenuated with centanamycin, TH-III-149, or AS-VIII-104, as 
indicated, or left untreated. All were challenged 5 weeks later with 105 P. chabaudi prbcs i.v. (C) To assess immunity in a different mouse strain, 
C57BL/6 mice were either immunized with a single dose of 106 P. chabaudi prbcs attenuated with centanamycin or given a saline injection (con-
trol) and challenged 9 weeks later with 105 P. chabaudi prbcs i.v. (D) TH-III-149 (for P. vinckei challenge) or centanamycin (for P. yoelii challenge) 
were used to attenuate P. chabaudi, and mice were immunized with a single dose of 106 prbcs and challenged 4 weeks later with either 104 
P. vinckei or 104 P. yoelii prbcs i.v. Plus signs indicate that mice succumbed to the infection.
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T cell engraftment was successful, as shown by flow cytometry 
with between 5% and 12% of peripheral blood T cells being of 
donor origin. Mice were challenged 11 days after transfer, but no 
protection was observed, despite control animals vaccinated with 
centanamycin-treated prbcs being protected.
We next asked whether mice immunized with either 104 or 106 
chemically attenuated parasites developed parasite-specific antibod-
ies. Using an ELISA to whole parasite antigens, we observed that 
while sera taken from mice that experienced multiple infections 
each followed by drug cure contained antibodies, sera from mice 
immunized with attenuated parasites did not (Supplemental Figure 
9A). In a repeat experiment to confirm protection in the absence of 
antibodies, we observed that not only were antibodies not detect-
able after vaccination, but that following challenge (during which 
parasites were not detectable by microscopy in any of the vaccinated 
recipients), antibodies were also not detected (Supplemental Figure 
9B). In a further experiment to ascertain any role for antibodies, sera 
from 10 vaccinated A/J mice and from 10 control mice were trans-
ferred into naive recipients (0.5 ml on each of days –1, 0, and 1) that 
were challenged on day 0. Mice that received serum from immunized 
mice as well as mice that received serum from naive controls all suc-
cumbed without any evidence of protection, but the serum donor 
mice were protected (Supplemental Figure 9C).
The above data suggest that antigen-presenting cells initiate 
an antiparasite CD4+ T cell response following uptake of rbcs 
containing attenuated parasites. To further understand the 
interactions between attenuated parasites and the cells of the 
immune system, we asked whether a preparation of lysed attenu-
ated prbcs would also induce immunity. We immunized mice 
with intact or lysed attenuated prbcs and observed that when 
the rbc membranes were disrupted, immunity was not induced 
(Figure 4A). Therefore, the interaction between the attenuated 
parasites and the cells of the immune system requires the rbc 
membranes to remain intact. As the spleen is assumed to be a 
site where antiparasite immunity is induced (ref. 24 and Figure 
2), we examined the importance of the spleen in the induction of 
protective immunity. We observed that, while eusplenic control 
mice could control parasite burden more effectively than sple-
nectomized control mice, both groups of vaccinated mice could 
control parasite burden very effectively and to a similar level at 
5 weeks after vaccination (Figure 4B). This demonstrated that 
short-term immunity could be induced and mediated in tissues 
other than the spleen, with one likely site being the liver (25, 
26). However, in an experiment in which mice were challenged 
12 weeks after vaccination, we observed that splenectomized 
mice were not protected, whereas sham-splenectomized mice 
were still protected. This may be due to the presence of spleen-
resident memory cells mediating protection at later time points 
with effector cells, which may have a different tissue localiza-
tion, mediating protection at earlier time points.
Figure 2
Tracking of attenuated parasites stained with DiI and HO. rbcs from a P. chabaudi–infected mouse (parasitemia, 39.8%; Supplemental Figure 5A) 
were treated with centanamycin, stained with DiI and HO, and then injected i.v. into naive AJ mice (3 mice, 5 × 107 cells per mouse). rbcs from an 
uninfected mouse were stained with DiI alone and injected into other mice (3 mice, 5 × 107 cells per mouse). DiI+HO– cells (nrbcs) or DiI+HO+ cells 
(prbcs) in the peripheral blood of recipient mice were analyzed over time by flow cytometry and the percentage of these cells of the total injected 
nrbcs or prbcs calculated based on an assumption of the recipient mice each containing a total of 5 × 109 rbcs (A). Spleen and liver cells of recipi-
ent mice were prepared by mechanical disruption. rbcs were gated and DiI+HO+ cells identified. The percentages of DiI+HO+ cells of the total rbcs 
in the spleen and liver were then calculated (B). Free rbcs were then lysed using NH4Cl-Tris buffer to allow estimation of rbc uptake by white cells. 
Percentages of DiI+HO+F4/80+ or DiI+HO+CD11c+ cells in total F4/80+ (C) or CD11c+ cells (D) in the spleen and liver were then calculated. Two 
independent experiments were performed (total n = 4–6 mice per time point), and representative graphs are shown. Means ± SEM are shown.
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Figure 3
Immune responses induced by chemically attenuated parasites. (A) C57BL/6 mice (12 per group) were vaccinated with 106 P. chabaudi 
prbcs attenuated with centanamycin or injected with saline. Phenotypes of blood CD4+ and CD8+ cells were assessed on days 5 and 21 
after vaccination. Values for means of the saline group were subtracted from values for each vaccinated mouse. Each circle represents 1 
mouse. Horizontal bars represent means. One sample t test was performed comparing values to the saline mean of zero. (B) Three A/J mice 
were immunized with 3 doses of vaccine (each, 106 centanamycin-attenuated P. chabaudi prbcs), and spleen cells from these and a naive 
mouse were collected 8 weeks after the last immunization and cultured with indicated antigens; uptake of 3H thymidine was determined after 
72 hours as described in Methods. (C) C57BL/6 mice (5 per group) were vaccinated with 106 P. chabaudi prbcs or equivalent nrbcs attenu-
ated with centanamycin and sacrificed on day 5. Spleen cells were stimulated in vitro for 4 hours with PMA and ionomycin in the presence of 
BFA and stained for IFN-γ. Percentage that was IFN-γ positive was determined by subtracting isotype control and values from mice injected 
with saline for CD4 and CD8 populations. (D) Three A/J mice were immunized with 3 doses of vaccine (each, 106 centanamycin-attenuated 
P. chabaudi prbcs), and spleen cells from these mice were collected 50 days after the last immunization, cultured with indicated antigens, 
and after 72 hours culture, supernatants collected and use for cytokine bead analysis as described in Methods. (E) C57BL/6 mice (CD45.2, 
5 per group) were adoptively transferred with OT-II T cells (CD45.1), and 1 group received ovalbumin peptide 323–339 mixed with LPS i.p. 
24 hours later, mice were immunized i.v. with 106 P. chabaudi prbcs or equivalent nrbcs attenuated with centanamycin. Mice were bled on 
day 6 after immunization and the phenotype of donor and recipient cells determined by flow cytometry. Percentages were calculated by 
subtracting values from mice receiving OT-II cells alone.
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We next determined whether centanamycin treatment would 
result in attenuation of the major human parasite P. falciparum. 
It was previously observed that centanamycin could kill P. falci-
parum in vitro (27). To analyze this further, we measured RNA 
transcription and DNA replication after centanamycin treatment 
of a synchronized P. falciparum culture containing initially only 
rings (Supplemental Figure 10). We showed that, over a 64-hour 
time period, very few centanamycin-treated cells progressed 
through the cell cycle and that there was near complete arrest 
of transcription. This level of attenuation is consistent with our 
observations in vivo (above).
Discussion
We show that vaccination with chemically attenuated rodent para-
sites induces long-lived strain- and species-transcendent immunity 
via a mechanism that is CD4+ T cell dependent. At early times after 
vaccination (5 weeks), immunity can occur independently of the 
spleen, but the spleen appears to play a critical role at later time 
points (12 weeks) during the memory phase of the response. Vac-
cine efficacy requires the presence of intact rbc membranes.
Although T cells are critical for protection, we observed that 
splenic CD4+ T cells did not transfer protection. There are 2 likely 
explanations. First, the protective T cells of the donor mice were in 
the tissues and not resident in the spleen when the spleen cell trans-
fer experiment was performed. As such, protective T cells may not 
be transferred in a spleen cell transfer experiment. The fact that the 
mature forms of this parasite (schizonts) reside in the tissues and 
are not found in peripheral blood lends support to the fact that the 
protective T cells may also reside in the deep tissues. While this is a 
possibility, we believe that this may be a less likely explanation since 
we have shown that T cells from the spleen of vaccinated mice can 
respond by proliferation and cytokine production to prbcs. Second, 
while T cells are critical for protection (Supplemental Figure 8), other 
cell types and/or other changes in the tissues may also be critical. For 
example, we know that immunized mice depleted of CD4+ T cells 
offer more resistance to infection than naive mice, suggesting that 
immune cells other than CD4+ T cells might also contribute to pro-
tection. Changes in splenic architecture have also been reported in 
mice following P. yoelii and P. chabaudi infection (28, 29), and we can-
not rule out the possibility that vaccine-induced immunity occurs 
with structural changes in the spleen or other tissues. Furthermore, 
it is known that the liver can play an important role in protection 
(25, 26). Thus, vaccination with attenuated parasites might also alter 
tissue architecture in various tissues to promote antiparasitic immu-
nity that cannot be replicated in a simple cell-transfer experiment in 
which normal unexposed mice are the recipients of immune cells. 
Further studies are underway to attempt to resolve this issue.
The seco-cyclopropyl pyrrolo indole compounds are known to 
bind within the minor groove of parasite DNA in AT rich sequenc-
es (19, 27), which are highly abundant in Plasmodium. While we 
cannot exclude that these chemicals may have other effects on the 
parasite, the data suggest that the primary role of the seco-cyclo-
propyl pyrrolo indoles is to alkylate the parasite’s AT-rich DNA, 
severely compromising its ability to replicate. It is possible that 
some parasites may escape complete attenuation and continue a 
limited replicative cycle in vivo; the data showing persisting but 
fluctuating levels of parasite DNA in vivo support the hypothe-
sis that active parasite replication may be occurring at a very low 
level. However, any such replication would appear to be limited, as 
transfer of blood from vaccinated mice to naive recipients (xeno-
diagnosis) failed to establish a patent infection. There are poten-
tial concerns regarding a replicating parasite vaccine, including 
whether a more virulent phenotype would emerge and whether or 
not transmission might occur to another individual. While our 
data suggest that these will not be of concern, this nevertheless is 
something that will need to be carefully studied in clinical trials.
The results presented here strongly suggest that antigens expressed 
during the ring stage are responsible for the induction of protective 
immunity. We cannot exclude the possibility that a vaccine based 
on other stages (e.g., trophozoites) would also be effective. We chose 
Figure 4
Vaccine protection requires an intact rbc membrane. The role of the spleen early (5 weeks) after vaccination. (A) To determine whether the rbc 
membrane must remain intact for vaccine efficacy, cohorts of 5 A/J mice were vaccinated with a single dose of 106 P. chabaudi prbcs attenuated 
with centanamycin or a vaccine lysed with distilled water, then returned to isotonicity with 2× PBS. Naive mice served as a control. Five weeks 
later, mice were challenged with 105 P. chabaudi prbcs i.v. and parasitemia monitored. Plus signs indicate that mice succumbed to the infec-
tion. (B) To determine the importance of the spleen to immunity early after vaccination, A/J mice were splenectomized and others had a sham 
splenectomy. Four weeks later, half were immunized i.v. with 3 doses of 106 P. chabaudi prbcs attenuated by treatment with centanamycin, each 
2 weeks apart. The other half received no treatment. Five weeks after the final dose of vaccine, all mice were challenged with 105 prbcs i.v. and 
parasitemia monitored. Plus signs indicate that mice succumbed to the infection.
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ring-stage parasites for these studies because they are readily har-
vested at more than 98% purity from the blood of infected mice, 
whereas the mature forms are sequestered in deep tissues. Whether 
the immune response induced by the ring-stage vaccine responds 
to all stages or simply the ring stages is not known. However, it is 
known that many antigens are expressed throughout the various rbc 
stages (www.PlasmoDB.org and ref. 30). It seems likely that vaccine-
induced CD4+ T cells are reactivated by the different blood stages 
of Plasmodium at the start of an infection and that they then pro-
mote a cell-mediated immune response that prevents further para-
site growth. Evidence from other studies (e.g., refs. 1, 2, 31, 32) col-
lectively suggests that these CD4+ T cell–dependent, cell-mediated 
mechanisms include macrophage activation, phagocytosis, and the 
release of small inflammatory molecules such as nitric oxide.
A critical question for vaccine development is whether the data 
observed in a rodent model using a P. chabaudi vaccine will trans-
late to an efficacious and safe multispecies vaccine for humans. 
While this question will only be satisfactorily answered following 
human clinical trials, the data presented here, and elsewhere (11, 
12), suggest that this approach will be successful. We show that 
the vaccine is effective in different strains of mice, that immunity 
is cross-species protective, and that attenuated parasites prepared 
using a different rodent malaria species, P. yoelii, are also highly 
effective. This is the first time, to our knowledge, that any vac-
cine preparation has shown protection against the highly virulent 
P. vinckei (24). We previously demonstrated that deliberate infec-
tion of human volunteers with a subpatent P. falciparum infection 
(in which the volunteers are drug treated before the microscopic 
appearance of parasites and clinical symptoms) induced profound 
T cell immunity to the parasite (11). Here, we extend this observa-
tion markedly by attenuating the parasites prior to administration 
and thus converting the original observation into a vaccine strat-
egy. Collectively, these data are consistent with the hypothesis that 
the target antigens for T cells in Plasmodium are highly conserved 
across species (14, 16), and because of this, a human parasite vac-
cine is likely to be effective.
Although a whole parasite vaccine without any human rbc mate-
rial may be preferable, we show that the intact rbc membrane is 
essential for efficacy. Our data suggest that the role of the rbc 
membrane is to target the parasite to the antigen-presenting cells, 
as has been shown for P. falciparum (33), thereby initiating the anti-
parasite immune response. The issue of safety in the preparation 
of a human vaccine using human rbcs will be addressed in part 
by preparing a P. falciparum vaccine in “universal donor” (trans-
fusion-grade blood group O negative) rbcs. This topic has been 
discussed (34–37) looking at the recent inoculations of healthy 
volunteers with infected rbcs to study immunity and the inocula-
tions of syphilis patients who received malaria therapy in the early 
20th century and of volunteers in the latter half of the century who 
received deliberate infections to test schizonticides. No adverse 
side effects were reported in these studies. Today, stringent quality 
assurance makes blood transfusions extremely safe.
Another question relevant to vaccine development is whether 
sufficient vaccine can be prepared at scale in vitro. While the dose 
of attenuated parasites required to induce immunity in humans 
is not known, we are encouraged by the ability of extremely low 
parasite densities to activate human T cells (11), which suggests 
that very low doses of attenuated parasites may suffice. In those 
studies, volunteers received approximately 30 infected rbcs and the 
infection was curtailed after one week.
While whole parasite vaccines were not considered a viable and 
effective option for malaria until 10 years ago (38), there are now 
concerted efforts to develop a whole parasite sporozoite vac-
cine using either irradiated parasites (39), genetically attenuated 
organisms (40), or via sporozoite exposure and drug treatment 
(41), with all these approaches entering clinical trials. This has 
been driven in large part by the limited efficacy of the leading 
subunit sporozoite vaccine, RTS,S (42). Despite a multitude of 
blood-stage subunit vaccine candidates, none have progressed 
to late-stage trials, underscoring the importance of considering 
whole parasite vaccines as alternate strategies for the blood stages 
as well. Thus, we present data that we believe for the first time 
show that a chemically attenuated blood-stage malaria vaccine is 
highly efficacious and exerts its effect via a different mechanism 
from that of subunit vaccine candidates. This makes it worthy of 
serious consideration as a new approach to developing a malaria 
vaccine. Furthermore, the strategy of chemical attenuation and 
vaccine development could prove very useful for other organisms, 
many of which are known to be susceptible to attenuation by seco-
cyclopropyl pyrrolo indoles (19).
Methods
Mice. Four- to six-week-old female A/J mice (H-2a), BALB/c congenic SCID 
(H-2d) and C57BL/6 (H-2b), and B6.SJL-PtprcaPep3b/BoyJArc (Ptprca), were 
purchased from the Animal Resource Centre (Willeton, Western Australia). 
Animals were maintained in a pathogen-free environment at the Griffith 
University Animal Facility.
Parasites. Cloned lines of P. chabaudi isolates AS and AJ, P. yoelii, and 
P. vinckei were obtained from The Queensland Institute of Medical 
Research from stock originally provided by Richard Carter (University 
of Edinburgh, United Kingdom). Stabilates were maintained by i.p. pas-
sage of 105 prbcs into naive recipients. PCR amplification of the MSP1 
genes was used to confirm parasite identity. Challenge infections were 
performed by i.v. injection of 105 prbcs. P. falciparum NF54 strain was 
obtained from Sanaria Inc. Parasitemia was monitored from thin blood 
smears stained with Giemsa or Diff-Quick (Bacto).
Complete medium for lymphocyte culture. RPMI 1640 (Gibco; Invitrogen) 
was supplemented with 10% heat inactivated FBS, penicillin (2 mM), 
streptomycin (1,000 U/ml), and 2-mercaptoethanol (0.05 mM) (Gibco; 
Invitrogen) to make complete medium.
PCR. For sample preparation and DNA extraction, 10, 20, or 50 μl of 
infected blood was collected at different time points in 200 μl of 0.9% 
saline. Blood samples were centrifuged at 11,000 g for 5 minutes to pellet 
the erythrocytes, and the supernatant was removed. Samples were frozen 
at –80°C prior to DNA extraction. Genomic DNA (gDNA) was extracted 
using a High Pure PCR Template Preparation Kit (Roche) following the 
manufacturer’s instructions. gDNA was eluted in 30 μl elution buffer.
DNA standards were prepared from a whole blood sample from an out-
bred Quackenbush mouse infected with P. chabaudi AS. Infected blood was 
collected through cardiac puncture. 98% of prbcs were at the ring stage. 
The parasite density was measured by microscopy, diluted to a concen-
tration of 9.5 × 108 prbcs/ml, aliquoted, and stored at –80°C. gDNA was 
extracted fresh for each PCR run from 10 μl of whole blood and serially 
diluted to 9.5 prbcs/ml. The data from all curves were analyzed using Bio-
Rad CFX manager 2.1 software. The log10 of each known concentration in 
the dilution series was plotted against the quantification cycle (Cq values) 
in a linear regression model.
qPCR was performed using a Bio-Rad CFX96 Real-Time PCR System. A 
68-bp region of the 18S ribosomal RNA (18S rRNA) gene of P. chabaudi AS 
(GenBank DQ241815.1) that does not contain any putative centanamy-
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cin-binding sites (AAA[A/T]) was selected as the amplification target. PCR 
primers and a TaqMan MGB probe were designed as follows: 18SNCB-
forward: 5′-ACTTCCATTAATCAAGAACGAAAGTT-3′, 18SNCB-reverse: 
5′-TGGTTAAGATTACGATCGGTATCTGA-3′ and 18SNCB-probe: FAM 
5′-AAGGGAGTGAAGACGA-3′ MGBNFQ (Applied Biosystems). The PCR 
mix consisted of 10 μl SsoFast Probes Supermix (Bio-Rad), 0.2 μM of each 
primer, and TaqMan MGB probe and 5 μl of template DNA in a 20 μl 
final reaction mix under the following conditions: 2 minutes incubation 
at 95°C, followed by 45 cycles of 95°C for 15 seconds and 60°C for 45 
seconds. The standards and samples were run in triplicate.
rbc lysis. For analysis of the need for rbc membranes to remain intact for 
immunogenicity, the packed rbc volume was measured and 4 times the 
volume of sterile distilled water was added to the packed cells. The cells 
were resuspended for 2 minutes; then double-strength PBS was added to 
restore tonicity. Sample was reconstituted to 5 × 106 equivalent prbcs/ml.
Attenuation and immunization. Infected blood was collected by cardiac 
puncture when parasitemia was between 30%–40% and 100 μl diluted to 10 
ml in warm serum-free RPMI. AS-I-145 (Centanamycin) (43), TH-III-149 
(tafuramycin A) (44), and ASVIII-104 (45) have been previously described. 
These were dissolved in DMSO at 10,000× the desired attenuating concen-
tration. Stock solutions of PET (polyethylene glycol 400, absolute ethanol, 
and Tween 80 in 6:3:1 portions) and 5% glucose were made and mixed 1:2. 
The DMSO solution was then added at 10% volume to the PET/glucose 
mix. Attenuating agents were diluted to a 20-μM final concentration in 
RPMI and then infected blood added in RPMI to give a final concentration 
of 2 μM. The mixture was then incubated at 37°C in a 5% CO2 incuba-
tor for 40 minutes. The cells were washed 3 times and counted, and the 
immunizing dose was calculated. Mice were immunized i.v. Control mice 
received treated nrbcs, saline, or no treatment, as described.
Analysis of P. falciparum attenuation. P. falciparum NF54 parasites were cul-
tivated at 37°C with 5% carbon dioxide/5% oxygen in air using O+ human 
erythrocytes (Australian Red Cross Blood Service) in RPMI 1640 contain-
ing 25 mM HEPES, 10% O+ human serum (Australian Red Cross Blood Ser-
vice), l-glutamine, and 25 mg/ml gentamycin (complete culture medium). 
Parasites were synchronized with sorbitol treatment and ring-stage para-
sites prepared (1.8 to 2.0% parasitemia). Parasites were treated with 2 μM 
centanamycin at 37°C for 40 minutes and then washed with serum free 
RPMI 1640 medium. WT or centanamycin-treated P. falciparum parasites 
were grown in complete medium for 64 hours and parasites collected every 
16 hours. The culture medium was replaced every 24 hours.
For RNA and DNA staining (46), rbcs were pelleted and resuspended in 
400 μl of Retic-COUNT Reagent (thiazole orange [TO]; BD), and then HO 
34580 added at a 4-mM final concentration. A total of 100,000 cells were 
collected by the LSRFortessa flow cytometer, and data were analyzed by 
FACSDiva software. HO and TO signals were detected by 450/50 (excited 
by 405 nm) and 530/30 (excited by 488 nm) filters, respectively.
Immunodepletion. Anti-CD4 antibodies were generated from the culture 
supernatant of rat anti-mouse CD4, clone GK1.5 (ATTC). Rat anti-mouse 
CD8β was generated from clone 53.5.8 (ATCC). Both were purified over a 
protein G–sepharose column (Thermo Scientific). 500 μg of anti-CD4 was 
administered on days –4, –3, –2, –1, 0, and +1 relative to challenge day. 500 μg 
of rat anti-CD8β was administered i.p. on days –4, –3, –2, –1, 0, +1, +3, and +5 
relative to the day of challenge. 500 μg of rat IgG (Sigma-Aldrich) was used as 
a control antibody. CD4 depletion was shown to be 99% effective, and CD8 
depletion was shown to be 98% complete using flow cytometry.
Lymphocyte proliferation assays. Mouse spleens were processed to obtain a 
single-cell suspension, diluted to 5 × 106 cells/ml in RPMI 1640 complete 
medium, and aliquoted into 96-well plates at 5 × 105 cells/well. Triplicate 
wells were cultured with fresh prbcs or nrbcs at 5 × 105/well. Cells were 
pulsed with 0.25 μCi of 3[H]-Thymidine (PerkinElmer)/well during the last 
18 hours of a 72-hour culture and harvested onto fiberglass mats; 3H incor-
poration was measured on a PerkinElmer MicroBeta2 β counter.
Analysis of circulating T cells. Approximately 50 μl of blood was obtained 
from the tail of each mouse. rbcs were lysed with ACK and Fc-receptors 
blocked with 100 μg/ml heat-inactivated rat IgG for 10 minutes on ice. 
Samples were stained for 20 minutes on ice with a biotinylated anti-
CD49d, followed by washing and staining with anti-CD4 V500 (clone RM 
4-5), anti-CD8 PerCP-Cy5.5 (clone 53-6.7), anti-CD11a FITC (clone 2D7), 
and streptavidin-APC (all from BD). Samples were fixed with 4% formal-
dehyde and run on a BD LSRFortessa. Data were analyzed with FlowJo; 
saline means were calculated and subtracted from samples using Excel and 
graphed using Prism 5 for Mac OS X. One-sample t tests (2 tailed) were 
performed with Graph Pad QuickCalcs software (http://www.graphpad.
com/quickcalcs/).
Adoptive transfer. Spleens from 2 female B6.OT-II.Ptprca (CD45.1) mice 
were placed into a 100-mm dish containing medium and a 70-μm nylon 
cell strainer. The plastic end of a 5-ml syringe was used to gently mash 
the spleens, and the cell suspension was strained through the same 70-μm 
strainer. The petri dish was rinsed with additional medium. The cell sus-
pension was centrifuged at 300 g for 5 minutes and supernatant aspirated. 
rbcs were lysed using 1× Vitalyse buffer for 5 minutes at room temperate 
and quenched with excess medium. Cells were centrifuged as above and 
isolated using the CD4+ T cell Isolation Kit II (Miltenyi Biotec) accord-
ing to the manufacturer’s recommendations. Cells were resuspended in 
0.9% saline and injected i.v. with either 500,000 or 100,000 cells (for I-Ab 
restricted chicken ovalbumin peptide 323–339, sequence ISQAVHAA-
HAEINEAGR, +LPS group) per mouse. The ovalbumin peptide group 
received 10 μg of LPS mixed with 30 μg of peptide administered i.p. After 
24 hours, mice received either nothing, 1 × 106 P. chabaudi AS centanamy-
cin attenuated prbcs, or equivalent numbers of centanamycin-attenuated 
naive rbcs administered i.v. Mice were tail bled approximately 50 μl on day 
6 after immunization (day 7 after adoptive transfer) and the phenotype 
of donor (OT-II, CD45.1+) and host (B6, CD45.2+) were assessed via flow 
cytometry. Cells were stained with antibodies against CD3, CD4, CD11a, 
CD49d, CD45.1, and CD45.2. The phenotype and purity of the adoptively 
transferred cells was also assessed and was found to be 80% CD3+CD4+.
T cell transfer for protection. Ten female Ptprca (CD45.1) mice received a 
single dose of 100 μg anti-CD4 monoclonal antibody (clone YTS191.1) 
i.v. on day 3 prior to adoptive transfer. Spleens from 5 female C57BL/6 
mice 3 days after the third immunization with 106 P. chabaudi AS centana-
mycin–attenuated prbcs or from naive C57BL/6 mice were processed (as 
described above for adoptive transfer) and CD4+ T cells isolated. 107 CD4+ 
T cells were injected i.v. per CD4-depleted Ptprca mouse. Mice were chal-
lenged with 105 P. chabaudi AS prbcs i.v. on day 11 after transfer. Addition-
ally, naive Ptprca mice and thrice immunized C57BL/6 that received either 
centamycin-attenuated nrbcs or P. chabaudi AS prbcs were all also chal-
lenged on the same day. Parasitemias and clinical scores were monitored. 
On day 7 after challenge, approximately 50 μl of blood was collected via 
tail from Ptprca mice that received no cells or CD4+ T cells from naive or 
immunized mice and evaluated for phenotype of host and recipient cells. 
Percent chimerism was calculated as the percentage of leukocytes that 
were CD3+CD4+CD45.2+CD45.1–.
Intracellular staining for IFN-γ. Spleens were individually processed in a 
well of a 6-well plate containing 5 ml medium and a 70-μm nylon cell 
strainer. The rubber end of a 10-ml syringe was used to gently mash 
each spleen, and the cell suspensions were strained through their respec-
tive 70-μm strainers. Each well was rinsed with additional medium. The 
cell suspension was spun at 400 g for 5 minutes and supernatant aspi-
rated. rbcs were lysed using 1× Vitalyse buffer for 5 minutes at room 
temperate and quenched with excess medium. Cells were spun as above 
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were blocked for 2 hours at room temperature with PBS/5% BSA. 100 μl 
of sera diluted 1/20 were added in triplicate, incubated 1 hour at room 
temperature, washed 5 times with PBS Tween 20 before HRP-conjugated 
total Ig, IgG1, or IgG2a (BD) were added, and incubated for 1 hour at room 
temperature. TMB (OptEIA substrate reagent set BD) was added and incu-
bated at room temperature for 30 minutes before adding 1N H2SO4 and 
reading optical density at 405 nm, using an ELISA reader.
Splenectomy. Mice were anesthetized with Buprenorphine analgesic (0.05 
mg/kg) given subcutaneously and splenectomy performed by Hamish 
McMath (Animal Facilities Manager, Griffith University).
Statistics. Unpaired t tests were performed (2 tailed), and values were con-
sidered significantly different at P < 0.05.
Study approval. All experiments were performed with the consent of the 
Griffith University Animal Ethics Committee. The use of human blood 
products for culture of P. falciparum was approved by the Griffith Univer-
sity Human Research Ethics Committee (approval # BDD/03/10/HREC). 
As part of standard Australian Red Cross Blood Service practice, donors 
consent each time they donate blood or blood products to the use of their 
donation for research purposes.
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and resuspended to 107 cells per ml and 100 μl (106) cells added per 
well into a round-bottomed 96-well plate. All wells received brefeldin 
A (BFA) at a final concentration of 10 μg/ml or with the addition of 5 
× 106 P. chabaudi AS prbcs or equivalent nrbcs or with final concentra-
tions of 0.1 μg/ml PMA and 0.1 μM ionomcyin (all from Sigma-Aldrich). 
Cells were cultured for 4 hours at 37°C and centrifuged at 400 g for 
5 minutes; supernatants were removed by flicking. Cells were washed 
with PBS and resuspended in PBS containing yellow live/dead fixable 
stain (Invitrogen) (1:100) and incubated for 30 minutes on ice protected 
from light. Cells were washed with PBS and Fc receptors blocked by 
incubating for 10 minutes on ice with 2.4 G2 antibody supernatant. 
Cells were centrifuged and resuspended in 50 μl of surface antibodies 
(CD4,CD8,CD11a,CD49d) in PBS and incubated on ice for 20 minutes. 
Cells were washed three times and resuspended in BD Fix/Perm buffer 
according to the manufacturer’s recommendations. Cells were subse-
quently stained with anti–IFN-γ or rat IgG1 isotype control antibodies 
in fix/perm wash buffer for 20 minutes on ice. After washing, cells were 
resuspended in 1% paraformaldehyde in PBS and kept at 4°C protected 
from light until run on a BD LSRFortessa cytometer.
Cytokine bead array. Three A/J mice were immunized with 3 doses of vac-
cine (each consisting of 106 centanamycin-attenuated P. chabaudi prbcs), 
and spleen cells from these mice were collected 50 days after the last 
immunization, cultured with indicated antigens (as described above for 
proliferation assay); after 72 hours, culture supernatants were collected. 
Supernatants from duplicate wells were used for the Mouse Inflammation 
Kit Cytometric Bead Array (BD) according to the manufacturer’s recom-
mendations, except that volumes of samples and standards were scaled 
down to 10 μl and 2 μl of each capture bead was used. Samples were run on 
a BD LSRFortessa cytometer and data analyzed with FCAP array (v1.01 for 
Windows) software (BD).
ELISA. To prepare crude parasite antigen, blood from mice infected with 
P. chabaudi AS at peak parasitemia was collected, washed in PBS, and incu-
bated with 0.01% (wt/vol) saponin (Sigma-Aldrich) at 37°C for 20 minutes. 
The pellet was washed in PBS, resuspended in PBS, and sonicated. 96-well 
MaxiSorp Nunc immunoplates (Nunc) were coated overnight at 4°C with 
10 μg of parasite antigen/ml in bicarbonate coating buffer (pH 9.6). Wells 
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